CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Top player positioning, 2019
3.4. Porters five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Rise in prevalence of infectious diseases
3.5.1.2. Development of novel approaches for new antibiotics for treating bacterial infections

3.5.2. Restraints

3.5.2.1. Development of antibiotic resistance
3.5.2.2. The time taken for the regulatory approval

3.5.3. Opportunities

3.5.3.1. Discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections.

3.5.4. Impact analysis

3.6. Impact of COVID-19 on European Antibiotic Market

CHAPTER 4: EUROPEAN ANTIBIOTIC MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Beta Lactam and Beta Lactamase Inhibitors

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market analysis, by country
4.2.3. Market size and forecast, by type

4.2.3.1. Penicillin

4.2.3.1.1. Market size and forecast

4.2.3.2. Cephalosporin

4.2.3.2.1. Market size and forecast

4.2.3.3. Carbapenem

4.2.3.3.1. Market size and forecast

4.2.3.4. Monobactam

4.2.3.4.1. Market size and forecast

4.3. Quinolone

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market analysis, by country

4.4. Macrolide

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market analysis, by country

4.5. Other

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market analysis, by country

CHAPTER 5: EUROPEAN ANTIBIOTIC MARKET, BY DRUG ORIGIN

5.1. Overview

5.1.1. Market size and forecast

5.2. Natural

5.2.1. Market analysis, by country

5.3. Semisynthetic

5.3.1. Market analysis, by country

5.4. Synthetic

5.4.1. Market analysis, by country

CHAPTER 6: EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY

6.1. Overview

6.1.1. Market size and forecast

6.2. Broad spectrum antibiotics

6.2.1. Market analysis, by country

6.3. Narrow spectrum antibiotics

6.3.1. Market analysis, by country

CHAPTER 7: EUROPEAN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION

7.1. Overview

7.1.1. Market size and forecast

7.2. Oral

7.2.1. Market analysis, by country

7.3. Intravenous

7.3.1. Market analysis, by country

7.4. Others

7.4.1. Market analysis, by country

CHAPTER 8: EUROPEAN ANTIBIOTIC MARKET, BY COUNTRY

8.1. Europe

8.1.1. Key market trends, growth factors, and opportunities
8.1.2. Market size and forecast, by country

8.1.2.1. Germany

8.1.2.1.1. Germany antibiotic Market, by drug class
8.1.2.1.2. Germany antibiotic market, by drug origin
8.1.2.1.3. Germany antibiotic market, by spectrum of activity
8.1.2.1.4. Germany antibiotic market, by route of administration

8.1.2.2. France

8.1.2.2.1. France antibiotic market, by drug class
8.1.2.2.2. France antibiotic market, by drug origin
8.1.2.2.3. France antibiotic market, by spectrum of activity
8.1.2.2.4. France antibiotic market, by route of administration

8.1.2.3. UK

8.1.2.3.1. UK antibiotic market, by drug class
8.1.2.3.2. UK antibiotic market, by drug origin
8.1.2.3.3. UK antibiotic market, by spectrum of activity
8.1.2.3.4. UK antibiotic market, by route of administration

8.1.2.4. Italy

8.1.2.4.1. Italy antibiotic market, by drug class
8.1.2.4.2. Italy antibiotic market, by drug origin
8.1.2.4.3. Italy antibiotic market, by spectrum of activity
8.1.2.4.4. Italy antibiotic market, by route of administration

8.1.2.5. Spain

8.1.2.5.1. Spain Antibiotic market, by drug class
8.1.2.5.2. Spain antibiotic market, by drug origin
8.1.2.5.3. Spain antibiotic market, by spectrum of activity
8.1.2.5.4. Spain antibiotic market, by route of administration

8.1.2.6. Rest of Europe

8.1.2.6.1. Rest of Europe antibiotic market, by drug class
8.1.2.6.2. Rest of Europe antibiotic market, by drug origin
8.1.2.6.3. Rest of Europe antibiotic market, by spectrum of activity
8.1.2.6.4. Rest of Europe antibiotic market, by route of administration

8.1.3. Europe antibiotics market, by drug class
8.1.4. Europe antibiotics market, by drug origin
8.1.5. Europe antibiotics market, by spectrum of activity
8.1.6. Europe antibiotics market, by route of administration

CHAPTER 9: COMPANY PROFILES

9.1. ABBOTT LABORATORIES

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance

9.2. ABBVIE INC.(ALLERGEN)

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments

9.3. BAYER AG.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance

9.4. F. HOFFMANN-LA ROCHE LTD.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.4.6. Key strategic moves and developments

9.5. GLAXOSMITHKLINE PLC

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance

9.6. MERCK & CO. INC.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments

9.7. VIATRIS INC.(MYLAN)

9.7.1. Company overview
9.7.2. Operating business segments
9.7.3. Product portfolio
9.7.4. Key strategic moves and developments

9.8. NOVARTIS INTERNATIONAL AG (SANDOZ)

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments

9.9. PFIZER INC.

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance

9.10. SANOFI

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
9.10.6. Key strategic moves and developments